Abstract

Summary Cladribine acts as an antineoplastic, immunosuppressive and anti-inflammatory agent. The aim of this study was to examine the possible impact of this drug on the epidermis of Wistar rats. The control group received standard feed and water. The experimental group I was treated with cladribine in a schema corresponding to the treatment of multiple sclerosis in humans. The material for microscopic and immunohistochemical evaluation was obtained 24 h after administration of the last dose of the drug. The drug in experimental group II was administered in the same way as experimental group I, but test material was downloaded following a 4 week break after the administration of the last dose of the drug. After the completion of the experiment, skin samples were taken from all rats for histomorphological and immunohistochemical studies. An analysis of experimental group I H&E samples showed visible changes in epidermis patterns, and the.tissue layer was found to be much thinner compared to the analogous structures in the control group. The difference in p53 expressions between the control and both experimental groups was found to be statistically significant (P<0.0001). Cladribine administration induces changes in the images of the epidermis of experimental animals. Based on morphological analysis and p53 protein expression, it can be concluded that the 4-week break in drug administration contributed to the regeneration of the rats’ skin epithelial tissue.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.